Modeling and Simulation - PK/PD Archives | Page 24 of 37

Publication

Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel

Pertuzumab is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined…

Certara2013年11月24日

On-Demand Webinar

Phoenix WinNonlin：A State of the Art Software Tool for Pre-clinical PK and TK Analysis

Are you currently using Excel for PK/TK analysis? Phoenix WinNonlin streamlines analyses and generates all…

Certara2013年11月21日

技術情報

What is Identifiability?

Developing models for pharmacokinetic or pharmacodynamic data requires creativity, patience, and hard work. Sometimes that…

Certara2013年11月18日

On-Demand Webinar

Introduction to Population PK/PD Analysis Using Phoenix NLME

Phoenix NLME provides sophisticated algorithms and powerful and flexible data processing and modeling tools for…

Certara2013年11月14日

Publication

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

The aim of this study was to assess the cardiovascular effects of a new inhaled…

Certara2013年11月1日

技術情報

What is the -2LL or the Log-likelihood Ratio?

Understand the 2LL (Log-likelihood Ratio) and its role in statistical analysis. Explore how it aids…

Certara2013年10月28日

Publication

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Categorizations of best response observed at week 8 of first-line treatment in two studies of…

Certara2013年10月22日

Knowledge Base

Using Sampling “Windows” for PK Blood Samples

One of the most common questions posed by clinical operations experts when including pharmacokinetic sampling…

Certara2013年10月15日

Publication

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

Certara2013年10月10日

技術情報

What is “Adjusted” r-squared?

Linear regression is a common tool that the pharmacokineticist uses to calculate elimination rate constants.…

Certara2013年10月7日

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation – PK/PD

Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel

Phoenix WinNonlin：A State of the Art Software Tool for Pre-clinical PK and TK Analysis

What is Identifiability?

Introduction to Population PK/PD Analysis Using Phoenix NLME

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

What is the -2LL or the Log-likelihood Ratio?

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Using Sampling “Windows” for PK Blood Samples

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

What is “Adjusted” r-squared?

メルマガ登録

クイックアクセス

ソリューション

お問合せ